% | $
Quotes you view appear here for quick access.

Ampio Pharmaceuticals, Inc. Message Board

  • superforce_57 superforce_57 Mar 12, 2013 10:46 AM Flag

    Shorts are really hammering AMPE this AM....

    ..they are trying to hold it down. Short interest is at an all time of 3,600,000 shares. Unfortunately the small float & daily trading volume allows the shorts to manipulate this stock.

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • It's so easy for the shorts to keep the price down, given that volume is so low. Why is there so little buying?

      Sentiment: Buy

    • mjakobczak9 Mar 14, 2013 12:59 PM Flag

      Are the shorts keeping those RKTE message "active" to scare away investors?

      Sentiment: Strong Buy

    • You are EXACTLY CORRECT!

      Management STILL has not figured out what you have. Small hedge funds that prey on low volume, invisible companies like Ampio because they are easy to manipulate. The have no following because they have no known investment bankers or known analysts. Ampio is an excellent target for the short players because Ampio management is completely blind and ignorant to how the stock market works. Ampio is exceptionally vulnerable to the shorts.

      Shares should get a good spike soon when the Zertane deal is announced but they would wind up much higher if they started for $10 or $20 rather than from $4.

      If management was as good with IR as they are are with developing their pipeline, Ampio would be at least a $20 dollar stock today and trading volume would average 10 million shares a day.

      Sentiment: Strong Buy

      • 1 Reply to tradersoracle
      • Management, particularly Macaluso & Bar-Or, own a ton of stock & obviously want to see the share price higher. I'm not sure how much more they can do in that regard other than going on a road show. But they don't have any approved drugs yet, and only Optina has started a Phase 3 trial. I'm not sure how this is a $10 or $20 stock yet without some positive news from Phase 3 trials. That being said, all of their 3 primary drug candidates address huge potential markets, and we'll have indications of efficacy from the trials on all 3 drugs before the end of the year. We don't need FDA approvals for the stock to soar, all we need are positive initial indications from the trials. Good Phase 3 data for just one of the drugs - Ampion, Optina, Zertane - will result in a double or triple. If 2 of the drugs succeed, then the sky is the limit.

0.75+0.01(+1.42%)Oct 24 4:02 PMEDT